INVO Bioscience, Inc. (INVO)

NASDAQ: INVO · IEX Real-Time Price · USD
0.605
0.00 (0.05%)
At close: Mar 29, 2023, 4:00 PM
0.610
+0.005 (0.78%)
Pre-market: Mar 30, 2023, 6:15 AM EDT
0.05%
Market Cap 7.62M
Revenue (ttm) 3.59M
Net Income (ttm) -8.27M
Shares Out 12.59M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 65,424
Open 0.605
Previous Close 0.605
Day's Range 0.605 - 0.640
52-Week Range 0.329 - 2.837
Beta 0.80
Analysts Sell
Price Target 2.04 (+237.02%)
Earnings Date May 15, 2023

About INVO

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida. [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2007
Employees 10
Stock Exchange NASDAQ
Ticker Symbol INVO
Full Company Profile

Financial Performance

In 2021, INVO's revenue was $4.16 million, an increase of 301.06% compared to the previous year's $1.04 million. Losses were -$6.65 million, -20.27% less than in 2020.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for INVO stock is "Sell." The 12-month stock price forecast is $2.04, which is an increase of 237.02% from the latest price.

Price Target
$2.04
(237.02% upside)
Analyst Consensus: Sell
Stock Forecasts

News

INVO Bioscience Announces Closing of $3.0 Million Registered Direct Offering

SARASOTA, Fla. , March 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment w...

2 days ago - PRNewsWire

INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market

SARASOTA, Fla. , March 24, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment w...

5 days ago - PRNewsWire

INVO Signs Binding Agreements to Acquire Wisconsin Fertility Institute

Accretive acquisition expected to add significant scale to INVO's operations Contributes  over $5 million in incremental annual revenue as well as positive net income Initial transaction that establis...

1 week ago - PRNewsWire

INVO Bioscience Enters Distribution Agreement for Taiwan

SARASOTA, Fla. , Jan. 5, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment wor...

2 months ago - PRNewsWire

INVO Bioscience Engages Nationally Recognized Physician for New Tampa-based INVO Center

Shelly W. Holmström, M.D. FACOG, to serve as physician operator at soon to be opened Tampa-based INVO Center.

3 months ago - PRNewsWire

First Baby Born in Malaysia Utilizing Innovative INVOcell Assisted Reproductive Technology

Patient was part of a prospective peer reviewed study of INVOcell compared to conventional IVF (cIVF) in Malaysia INVOcell provides an advanced, effective and affordable infertility treatment option t...

4 months ago - PRNewsWire

INVO Bioscience Reports Third Quarter 2022 Financial Results

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , Nov. 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company f...

4 months ago - PRNewsWire

INVO Bioscience to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , Nov. 10, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-sta...

4 months ago - PRNewsWire

INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo

-     The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimate...

5 months ago - PRNewsWire

INVOcell Review Published in Current Opinion in Obstetrics and Gynecology

SARASOTA, Fla. , Oct. 21, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ...

5 months ago - PRNewsWire

Invo BioScience Inc. (INVO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Invo BioScience Inc. (INVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...

6 months ago - Zacks Investment Research

Invo BioScience Inc. (INVO) Upgraded to Buy: Here's What You Should Know

Invo BioScience Inc. (INVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

7 months ago - Zacks Investment Research

INVOcell Launched in Malaysia by Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz

SARASOTA, Fla. , Aug. 25, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ...

7 months ago - PRNewsWire

INVO Bioscience Reports Second Quarter 2022 Financial Results

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , Aug. 15, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company f...

8 months ago - PRNewsWire

INVO Bioscience to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , Aug. 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stag...

8 months ago - PRNewsWire

INVO Bioscience Announces "Get to Know INVOcell" - a Series of Facebook Live Events Supporting Access to Affordable Fertility Treatment

Mark Your Calendars for July 7, 2022, with Dr. Sue Ellen Carpenter of Atlanta-based Bloom Fertility SARASOTA, Fla. , July 7, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "C...

9 months ago - PRNewsWire

INVO Signs Distribution Agreement with Onesky Holding Limited for Mainland China

Agreement includes minimum purchase obligations upon product registration and approval SARASOTA, Fla. , May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a c...

11 months ago - PRNewsWire

INVO Bioscience Reports First Quarter 2022 Financial Results

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company foc...

11 months ago - PRNewsWire

INVO Bioscience to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , May 9, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage...

11 months ago - PRNewsWire

INVO Celebrates National Infertility Awareness Week at the INVO Center in Atlanta, Georgia

Bloom Fertility, an INVO Center to grant three eligible patients a full IVC treatment cycle SARASOTA, Fla. , April 28, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fer...

11 months ago - PRNewsWire

INVO Selects Kansas City as additional INVO Center Location

U.S. Market Expansion Continues as Planned SARASOTA, Fla. , April 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused ...

1 year ago - PRNewsWire

INVO Bioscience to Participate in the Lytham Partners Spring 2022 Investor Conference

SARASOTA, Fla. , April 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell®...

1 year ago - PRNewsWire

INVO Bioscience Reports 2021 Financial Results

Company to Host Conference Call Today at 4:30pm ET; Slide Presentation Also Available SARASOTA, Fla. , March 31, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a ...

1 year ago - PRNewsWire